*Purpose: Liver transplants are essential procedures that can impact a patient with chronic liver disease’s overall survival. Historically liver biopsies are the gold standard in staging liver fibrosis and steatosis; this is an invasive procedure which carries a risk of significant bleeding and possible skewed results of the whole liver. This puts the recipient at risk for poor graft function and increasing the possibility for re-transplantation. A noninvasive alternative to liver biopsy is Fibroscan, also known as liver ultrasonographic elastography, which can stage liver fibrosis and fatty changes within the liver. It is hypothesized that Fibroscan can predict liver transplant success, immediate function (IF), and 1 year function as a non-invasive alternative to the liver biopsy.

*Methods: A single OPO, [SS1] cohort study of all patients over 16 years old undergoing both a liver biopsy and Fibroscan through the Midwest Transplant Network (MTN). Fibroscan functionality scores included the patient’s Vibration-controlled Transient Elastography (VCTE) score for fibrosis, Controlled Attenuation Parameter (CAP) score for steatosis, comparing to intra-op liver biopsy. Statistical analysis was performed by Chi-square test with p<0.05 as significant.

*Results: 24 consecutive patients were identified and underwent Fibroscan producing VCTE and CAP scores indicative of viable liver function (<11and <248 respectively). There was no statistical difference between the VCTE (p<0.61) and CAP scores (p<0.192) predictability of immediate function. As of publishing of this abstract the 1-year function could not be confirmed as the liver was either functioning or follow up could not be obtained. Liver biopsies correlated completely with IF.

*Conclusions: A statistically significant finding of Fibroscan scores (VCTE and CAP) being able to predict whether a liver would have IF or be accepted for transplant was not found. There was a trend and clinically significant difference in the VCTE score being predictive. The study was limited by the sample size and lack of quantifiable data from the 1-year follow-up. A multicenter prospective study should be considered to further evaluate the effectiveness of liver evaluation with Fibroscan.

« Back to 2022 American Transplant Congress